RxDoctor Payments Data

Cheryl Dann

Psychiatric/Mental Health · Tacoma, WANPI 1225673817

Payments from drug & device makers

$845in general payments, 2019–2025

Across 40 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$239
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$114
  • Johnson & Johnson$100
  • Otsuka America Pharmaceutical, Inc.$78
  • AbbVie$76
  • Neurocrine Biosciences, Inc.$76
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$845 in reported general payments places this provider in the 70th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$9,270
Medicare patients
16
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate86$311,416
Austedo XrDeutetrabenazine17$169,791
IngrezzaValbenazine Tosylate11$106,349
VraylarCariprazine Hcl36$49,840
RexultiBrexpiprazole14$20,662
Clozapine189$14,814
TrintellixVortioxetine Hydrobromide14$6,900
Paliperidone ErPaliperidone47$6,821
Divalproex Sodium95$5,274
Quetiapine Fumarate156$4,119
Lurasidone Hcl53$3,837
Olanzapine128$3,408
Bupropion XlBupropion Hcl50$3,362
Risperidone171$2,733
Fluphenazine Hcl15$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$100$311,41686 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$239$169,79117 claims
Neurocrine Biosciences, Inc.Ingrezza$76$106,34911 claims
AbbVieVraylar$76$49,84036 claims
Otsuka America Pharmaceutical, Inc.Rexulti$78$20,66214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →